BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 27462152)

  • 1. Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside.
    Zatsepin TS; Kotelevtsev YV; Koteliansky V
    Int J Nanomedicine; 2016; 11():3077-86. PubMed ID: 27462152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid nanoparticles for short interfering RNA delivery.
    Leung AK; Tam YY; Cullis PR
    Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
    Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
    Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
    Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
    Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of RNAi therapeutics: work in progress.
    Miller AD
    Expert Rev Med Devices; 2013 Nov; 10(6):781-811. PubMed ID: 24195461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-based nanoparticles in the systemic delivery of siRNA.
    Lin Q; Chen J; Zhang Z; Zheng G
    Nanomedicine (Lond); 2014 Jan; 9(1):105-20. PubMed ID: 24354813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery.
    Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T
    Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid Nanoparticle Systems for Enabling Gene Therapies.
    Cullis PR; Hope MJ
    Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
    Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
    Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility.
    Kulkarni JA; Cullis PR; van der Meel R
    Nucleic Acid Ther; 2018 Jun; 28(3):146-157. PubMed ID: 29683383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells.
    Uemura Y; Naoi T; Kanai Y; Kobayashi K
    Pharm Dev Technol; 2019 Mar; 24(3):263-268. PubMed ID: 29688101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle-siRNA: A potential cancer therapy?
    Young SW; Stenzel M; Yang JL
    Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-based siRNA Nanodelivery Systems: A Learning Process for Improving Transfer from Concepts to Clinical Applications.
    PĂ©rez SE; Carlucci AM
    Curr Clin Pharmacol; 2018; 13(3):142-163. PubMed ID: 30160217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-Generation Lipids in RNA Interference Therapeutics.
    Rietwyk S; Peer D
    ACS Nano; 2017 Aug; 11(8):7572-7586. PubMed ID: 28727419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
    Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
    J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming the Challenges of siRNA Delivery: Nanoparticle Strategies.
    Shajari N; Mansoori B; Davudian S; Mohammadi A; Baradaran B
    Curr Drug Deliv; 2017; 14(1):36-46. PubMed ID: 27538460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance.
    Zhang J; Pei Y; Zhang H; Wang L; Arrington L; Zhang Y; Glass A; Leone AM
    Mol Pharm; 2013 Jan; 10(1):397-405. PubMed ID: 23210488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polydispersity characterization of lipid nanoparticles for siRNA delivery using multiple detection size-exclusion chromatography.
    Zhang J; Haas RM; Leone AM
    Anal Chem; 2012 Jul; 84(14):6088-96. PubMed ID: 22816783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.